Clinics and Research in Hepatology and Gastroenterology
Original articleIncreased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms
Introduction
Cholangiocarcinoma (CCA) is an uncommon malignant cancer that arises from the neoplastic transformation of cholangiocytes anywhere along the intrahepatic and extrahepatic biliary tree, excluding the papilla of Vater and the gall bladder [1]. CCA can be classified as intra-hepatic (IHCC) or extrahepatic (EHCC), the latter being further subdivided into hilar, middle and distal carcinomas, based on the location of the tumor within the extrahepatic biliary tract. Despite novel advances in diagnosis and pathogenesis, in the majority of cases the etiology of CCA still remains obscure. However, several conditions associated with inflammation and cholestasis have been defined as risk factors for CCA. Furthermore, CCA likely results from neoplastic transformation of cholangiocytes, although transformation of epithelial cells within the peribiliary glands and/or biliary stem cells may also contribute to its development [2], [3], [4].
The circulating renin-angiotensin system (RAS) is known to play a crucial role in regulating blood pressure, blood flow, fluid volume and electrolyte balance [5], [6]. In addition to these well-known physiologic effects on cardiovascular and renal systems, local tissue RAS has been described to exist in tissues such as kidneys, gonads, adipose tissue, liver, pancreas and bone marrow from which it can elicit various specific responses for individual tissue functions [7], [8], [9], [10], [11], [12], [13], [14]. Angiotensin-converting enzyme (ACE), an important molecule of the RAS, is also considered to be a regulatory molecule in systemic and local circulation in distinct disorders. ACE catalyzes the conversion of Angiotensin I (Ang I) to Angiotensin II (Ang II) and is known to play a pivotal role in RAS [7], [15]. Although there is a considerable amount of data reporting the inevitable role of RAS in a variety of inflammatory and neoplastic disorders, there is only one study in the literature demonstrating the role of Ang II in the context of RAS that induces tumor progression and fibrosis in IHCC through an interaction with hepatic stellate cells [16]. The aim of the present study was to assess circulating ACE concentrations in biliary disorders including EHCC and choledocholithiasis (CL). Elucidation of the associations between ACE in the context of RAS and EHCC may help provide a better understanding of the enigmatic pathogenesis of EHCC.
Section snippets
Patients and methods
The present study was carried out in our tertiary reference center (Turkiye Yuksek Ihtisas Training and Research Hospital, Department of Gastroenterology) between July 2010 and February 2011. The study groups comprised 19 cases with EHCC (16 patients with hilar, three patients with distal CCA), 15 CL patients and 15 healthy controls. The diagnosis of CL was based on clinical and biochemical features of CL and also confirmed by radiological tools (ultrasonography, magnetic resonance
Results
The median age of patients with EHCC, CL and healthy controls were 67 (48–82), 65 (29–87), and 56 (23–74) respectively. There were no statistically significant differences between the ages of the study participants. Clinical characteristics and complete blood cell count values of study participants are summarized in Table 1. Biochemical tests of the cases with biliary disorders and the control group are summarized in Table 2. With respect to routine biochemical tests between the study groups,
Discussion
In the present study, we demonstrated that patients with EHCC have elevated circulating ACE concentrations in comparison with CL patients and healthy controls. The results of this study added a clue to the hypothesis that elevated ACE levels in the context of RAS could be linked to pathological biliary epithelial events in the microenvironment of the cholangiocytes that line the biliary tree (Fig. 2). Furthermore, elevated ACE levels are considered to have a role in the cytokine network of the
Disclosure of interest
The authors declare that they have no conflicts of interest concerning this article.
Acknowledgement
We would like to thank Dr. Sureyya Altunay, who helped us to prepare the Fig. 2 in this manuscript.
References (30)
- et al.
Cholangiocarcinoma
Crit Rev Oncol Hematol
(2009) - et al.
Intrahepatic cholangiocarcinoma arising in cirrhotic liver frequently expressed p63-positive basal/stem-cell phenotype
Pathol Res Pract
(2006) - et al.
Molecular pathology of biliary tract cancers
Cancer Lett
(2007) - et al.
Changes of angiotensin-converting enzyme activity in the pancreas of chronic hypoxia and acute pancreatitis
Int J Biochem Cell Biol
(2003) - et al.
Regulated expression of pancreatic renin-angiotensin system in experimental pancreatitis
Mol Cell Endocrinol
(2000) - et al.
Expression and localization of AT1 receptors in hepatic Kupffer cells: its potential role in regulating a fibrogenic response
Regul Pept
(2003) - et al.
Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways
Lab Invest
(2002) - et al.
Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor VEGF, and angiopoietin
Am J Pathol
(2003) - et al.
Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors
Kidney Int
(2002) - et al.
Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma
Am J Pathol
(1989)
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment
Hepatology
Local bone marrow renin-angiotensin system and atherosclerosis
Cardiol Res Pract
The renin-angiotensin system and its receptors
J Cardiovasc Pharmacol
Serum angiotensin converting enzyme levels in pancreatic diseases
Hepatogastroenterology
Elevated levels of circulating angiotensin converting enzyme in patients with hepatoportal sclerosis
Dig Dis Sci
Cited by (17)
Angiotensin-converting enzyme insertion/deletion polymorphism and gastric cancer: A systematic review and meta-analysis
2015, Clinics and Research in Hepatology and GastroenterologyCitation Excerpt :Characterized by absence of a 287-bp Alu repetitive sequence, the variant D allele carriers were reported to have higher ACE level and imposed different influence on blood vessels [11]. Previous studies indicated the ACE I/D polymorphism might be a risk factor for development of many human disorders [12–15]. Recently, the essential role of this polymorphism has been revealed in human cancers, such as esophageal and colorectal cancer [16,17].
Angiotensin II Receptor Antagonist, Valsartan, Has Beneficial Effect in Lung Metastasis of Colorectal Cancer Treated with Fluorouracil
2023, Journal of Gastrointestinal CancerGastrointestinal cancers, ACE-2/TMPRSS2 expression and susceptibility to COVID-19
2021, Cancer Cell InternationalComprehensive landscape of the renin-angiotensin system in pan-cancer: A potential downstream mediated mechanism of sars-cov-2
2021, International Journal of Biological Sciences